The company has a diverse product portfolio that includes DC Bead, a liver cancer treatment approved in 40 countries worldwide, and ondansetron RapidFilm, an oral thin film formulation used to prevent nausea and vomiting caused by chemotherapy, radiotherapy, and surgery. In addition, SciClone is developing SCV-07 for the delay of onset of severe oral mucositis in cancer patients and for the treatment of hepatitis C virus, as well as Thymalfasin for improvement of Influenza A (H1N1) vaccination. The company has an integrated platform for product development and commercialization, with a strategic focus on fast-growing therapeutic areas with unmet medical needs in China, particularly oncology and severe infection. Its revenue primarily comes from the sale of Zadaxin to Sinopharm.